Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI South East AsiaCPhI South East Asia
Not Confirmed
Not Confirmed
16-18 July, 2025
Discovery EuropeDiscovery Europe
Not Confirmed
Not Confirmed
01-02 July, 2025
Indo Livestock ExpoIndo Livestock Expo
Not Confirmed
Not Confirmed
02-04 July, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI South East AsiaCPhI South East Asia
Industry Trade Show
Not Confirmed
16-18 July, 2025
Discovery EuropeDiscovery Europe
Industry Trade Show
Not Confirmed
01-02 July, 2025
Indo Livestock ExpoIndo Livestock Expo
Industry Trade Show
Not Confirmed
02-04 July, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/alchem-nicselect-grants-customers-royalty-free-access-to-t-max-tech-for-3-in-1-vape-satisfaction-in-flavour-restricted-markets
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/j-j-s-intra-cellular-buyout-bms-oncology-gambit-sanofi-s-blueprint-acquisition-drive-mega-deals-in-h1-2025
14 Jan 2025
// PRESS RELEASE
https://www.gsk.com/en-gb/media/press-releases/gsk-enters-agreement-to-acquire-idrx-inc/
14 Nov 2024
// BUSINESSWIRE
07 Aug 2024
// BUSINESSWIRE
03 Jun 2024
// BUSINESSWIRE
27 Mar 2024
// BUSINESSWIRE
12 Mar 2024
// BUSINESSWIRE
Details:
Through this acquisition, GSK will expand its gastrointestinal cancer portfolio with IDRX-42. IDRX-42 is a highly selective KIT TKI developed for treating gastrointestinal stromal tumors.
Lead Product(s): IDRX-42
Therapeutic Area: Oncology Brand Name: IDRX-42
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: GSK
Deal Size: $1,150.0 million Upfront Cash: $1,000.0 million
Deal Type: Acquisition January 13, 2025
GSK Enters Agreement to Acquire IDRx, Inc.
Details : Through this acquisition, GSK will expand its gastrointestinal cancer portfolio with IDRX-42. IDRX-42 is a highly selective KIT TKI developed for treating gastrointestinal stromal tumors.
Product Name : IDRX-42
Product Type : Other Small Molecule
Upfront Cash : $1,000.0 million
January 13, 2025
Details:
IDRX-42 is a novel, KIT inhibitor that has potent activity against both the key activating mutations and broad coverage of the clinically relevant resistance mutations in KIT-driven GIST.
Lead Product(s): IDRX-42
Therapeutic Area: Oncology Brand Name: IDRX-42
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 14, 2024
IDRx Shares Phase 1 Data for IDRX-42 in Advanced GIST at CTOS 2024
Details : IDRX-42 is a novel, KIT inhibitor that has potent activity against both the key activating mutations and broad coverage of the clinically relevant resistance mutations in KIT-driven GIST.
Product Name : IDRX-42
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 14, 2024
Details:
The proceeds will support the ongoing clinical trial of its lead product IDRX-42l, targeting all major categories of activating & resistance mutations in patients with KIT-mutant GIST.
Lead Product(s): IDRX-42
Therapeutic Area: Oncology Brand Name: IDRX-42
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: RA Capital Management
Deal Size: $120.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing July 08, 2024
IDRx Announces $120M Series B to Advance New Treatment for Gastrointestinal Stromal Tumor
Details : The proceeds will support the ongoing clinical trial of its lead product IDRX-42l, targeting all major categories of activating & resistance mutations in patients with KIT-mutant GIST.
Product Name : IDRX-42
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 08, 2024
Details:
IDRX-42 is a novel, KIT inhibitor that has potent activity against both the key activating mutations and broad coverage of the clinically relevant resistance mutations in KIT-driven GIST.
Lead Product(s): IDRX-42
Therapeutic Area: Oncology Brand Name: IDRX-42
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 06, 2024
IDRx Updates Phase 1 Data Supporting IDRX-42 in GIST Patients
Details : IDRX-42 is a novel, KIT inhibitor that has potent activity against both the key activating mutations and broad coverage of the clinically relevant resistance mutations in KIT-driven GIST.
Product Name : IDRX-42
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 06, 2024
Details:
IDRx’s pipeline includes IDRX-42 and IDRX-73, small molecule tyrosine kinase inhibitors acquired through license agreements with Merck KGaA, Darmstadt, Germany, and Blueprint Medicines, respectively.
Lead Product(s): IDRX-42
Therapeutic Area: Gastroenterology Brand Name: IDRX-42
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: Andreessen Horowitz
Deal Size: $122.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing February 08, 2022
Lead Product(s) : IDRX-42
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Andreessen Horowitz
Deal Size : $122.0 million
Deal Type : Series A Financing
Details : IDRx’s pipeline includes IDRX-42 and IDRX-73, small molecule tyrosine kinase inhibitors acquired through license agreements with Merck KGaA, Darmstadt, Germany, and Blueprint Medicines, respectively.
Product Name : IDRX-42
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 08, 2022
ABOUT THIS PAGE